Arcturus Therapeutics Holdings Inc

(NASDAQ:ARCT)

Latest On Arcturus Therapeutics Holdings Inc (ARCT):

Date/Time Type Description Signal Details
2023-05-11 16:55 ESTNewsArcturus raised to Buy at H.C. Wainwright on prospects for COVID shotN/A
2023-05-10 00:15 ESTNewsArcturus Therapeutics GAAP EPS of $1.87 beats by $1.46, revenue of $80.29M beats by $30.83MN/A
2023-05-10 00:14 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 21:14 ESTNewsArcturus Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-12 00:46 ESTNewsUnlocking Arcturus' Potential And De-Risking Through PartnershipsN/A
2023-03-29 09:24 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call TranscriptN/A
2023-03-28 18:53 ESTNewsArcturus Therapeutics EPS of $4.33, revenue of $160.29M beats by $79.77MN/A
2023-03-28 18:53 ESTNewsArcturus Therapeutics up 21% after hours on quarterly beats, cash runway extensionN/A
2023-03-28 03:22 ESTNewsArcturus Therapeutics Q4 2022 Earnings PreviewN/A
2023-02-01 14:01 ESTNewsArcturus' mRNA Platform: The Future Of Quick And Efficient Vaccine DeliveryN/A
2023-01-31 12:48 ESTNewsArcturus' mRNA therapy for cystic fibrosis cleared for early-stage trial in New ZealandN/A
2022-11-15 15:34 ESTNewsArcturus Therapeutics Should Benefit From A Variety Of Positive DevelopmentsN/A
2022-11-11 06:26 ESTNewsArcturus downgraded at Baird on delayed catalyst and uncertainties in CSL dealN/A
2022-11-10 13:18 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 20:42 ESTNewsArcturus Therapeutics GAAP EPS of -$1.33 beats by $0.44, revenue of $13.4M beats by $9.31MN/A
2022-11-09 02:35 ESTNewsArcturus Therapeutics Q3 2022 Earnings PreviewN/A
2022-11-03 23:27 ESTNewsArcturus Therapeutics upgraded to buy at Citi on CSL Seqirus collaborationN/A
2022-11-02 13:47 ESTNewsArcturus Therapeutics announces collaboration with CSL SeqirusN/A
2022-11-02 13:47 ESTNewsAMD, JD and BILI are among pre market gainersN/A
2022-09-01 02:13 ESTNewsArcturus rises 6% on $63.2M award from U.S. government for mRNA vaccineN/A
2022-08-10 12:44 ESTNewsAcrturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-10 12:44 ESTNewsArcturus Therapeutics downgraded to underperform at Raymond James on program setbacksN/A
2022-08-09 18:58 ESTNewsArcturus Therapeutics GAAP EPS of -$0.82 beats by $1.04, revenue of $27.09M beats by $24.58MN/A
2022-08-08 19:55 ESTNewsArcturus Therapeutics Q2 2022 Earnings PreviewN/A
2022-06-22 15:45 ESTNewsArcturus gains 8% yesterday on takeover interest, blog report claimsN/A
2022-06-07 08:37 ESTNewsArcturus: Potential Based On Rare Disease Therapy ARCT-810N/A
2022-05-10 02:23 ESTNewsArcturus Therapeutics GAAP EPS of -$1.94 misses by $0.63, revenue of $5.24M misses by $1.84MN/A
2022-05-10 02:22 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 19:53 ESTNewsArcturus Therapeutics Q1 2022 Earnings PreviewN/A
2022-04-25 17:54 ESTNewsArcturus: Biotech With Great Potential In Covid-19 Vaccine SpaceN/A
2022-04-21 15:26 ESTNewsArcturus cut to Neutral at Citi on COVID vaccine ARCT-154 'too risky' path aheadN/A
2022-04-21 01:19 ESTNewsArcturus falls even as Piper Sandler backs COVID-19 vaccine dataN/A
2022-04-20 10:11 ESTNewsArcturus announces 95% overall efficacy for mRNA-based COVID-19 shotN/A
2022-03-22 17:29 ESTNewsArcturus gains with positive views from Piper Sandler on COVID-19 boosterN/A
2022-03-01 03:13 ESTNewsArcturus Therapeutics GAAP EPS of -$1.47 beats by $0.16, revenue of $5.8M misses by $5.85MN/A
2022-03-01 03:13 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 07:15 ESTNewsArcturus Therapeutics Q4 2021 Earnings PreviewN/A
2022-01-25 09:15 ESTNewsArcturus says messenger RNA vaccines raised antibody levels as boosters against OmicronN/A
2022-01-24 17:14 ESTNewsArcturus Therapeutics falls 9% amid announcement of COVID-19 booster study dataN/A
2021-12-16 23:03 ESTNewsArcturus gains after announcing early data from COVID-19 booster studyN/A
2021-11-29 02:58 ESTNewsArcturus: Emerging Covid Variants May Provide A Raison D'êTreN/A
2021-11-23 17:34 ESTNewsNanotechnology ETF is launched by Direxion SharesN/A
2021-11-09 04:02 ESTNewsArcturus Therapeutics EPS misses by $0.72, misses on revenueN/A
2021-11-09 04:02 ESTNewsArcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-08 07:45 ESTNewsArcturus Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-26 12:35 ESTNewsPiper Sandler initiates Arcturus with a buy on COVID vaccine included in WHO trialN/A
2021-10-12 20:39 ESTNewsVietnam health agency OKs phase 3b of Arcturus trial of SARS-CoV-2 vaccineN/A
2021-10-07 05:05 ESTNewsMerck eyeing more M&A deals as patent cliff for key cancer drug nears - FTN/A
2021-09-22 21:42 ESTNewsArcturus gets approval for ARCT-154 COVID-19 vaccine trials in VietnamN/A
2021-09-21 12:24 ESTNewsArcturus Therapeutics (ARCT) Investor Presentation - SlideshowN/A

About Arcturus Therapeutics Holdings Inc (ARCT):

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

See Advanced Chart

General

  • Name Arcturus Therapeutics Holdings Inc
  • Symbol ARCT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 118
  • Last Split Factor1:7
  • Last Split Date2017-11-16
  • Fiscal Year EndDecember
  • IPO Date2020-04-16
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.arcturusrx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 109.33
  • Price/Book (Most Recent Quarter) 3.4
  • Enterprise Value Revenue 86.83
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$3.67
  • Next Year EPS Estimate $7.69
  • Next Quarter EPS Estimate -$0.70
  • Operating Margin -750%
  • Return on Assets -16%
  • Return on Equity -34%
  • Revenue 9.54 million
  • Earnings Per Share -$1.26
  • Revenue Per Share $0.47
  • Gross Profit -48307000
  • Quarterly Earnings Growth -24.6%
View More

Highlights

  • Market Capitalization 1.27 billion
  • EBITDA -11472000
  • PE Ratio -7.9
  • Analyst Target Price $86.15
  • Book Value Per Share $15.14
View More

Share Statistics

  • Shares Outstanding 26.28 million
  • Shares Float 21.5 million
  • % Held by Insiders 1843%
  • % Held by Institutions 70.46%
  • Shares Short 3.19 million
  • Shares Short Prior Month 2.59 million
  • Short Ratio 3
  • Short % of Float 15%
  • Short % of Shares Outstanding 12%
View More

Technicals

  • Beta 2.93
  • 52 Week High $129.71
  • 52 Week Low $11.71
  • 50 Day Moving Average 62.88
  • 200 Day Moving Average 61.73
View More

Dividends

  • Dividend Date 2017-11-16
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Arcturus Therapeutics Holdings Inc (ARCT) Dividend Calendar:

ARCT's last dividend payment was made to shareholders on November 16, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Arcturus Therapeutics Holdings Inc (ARCT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-01$N/A-$1.25-$0.86-45.33%
2020-09-302020-11-09$N/A-$0.92-$0.49-87.49%
2020-06-302020-08-10$2.32 million-$0.55-$0.550.31%
2020-03-312020-05-07$2.65 million-$0.67-$0.59-13.83%
2019-12-312020-03-11$2.97 million-$0.76-$0.51-49.61%
2019-09-302019-11-08$3.32 million-$0.56-$0.46-20.87%
2019-06-302019-08-14$10.15 million-$0.07-$0.6188.6%
2019-03-312019-05-13$4.35 million-$0.68-$0.60-13.96%
2018-12-312019-03-18$7.58 million-$0.09-$0.5282.69%
2018-09-302018-11-07$3.42 million-$0.42-$0.35-20%
2018-06-302018-09-28$2.39 million-$0.99-$0.34-191.18%
2018-03-312018-05-14$2.38 million-$1.08-$0.46-134.78%
2017-12-312018-02-15$2.02 million-$0.11
2017-09-302017-11-09$3.3 million-$0.70-$2.6673.68%
2017-06-302017-08-11$3.76 million-$0.91-$0.943.19%
2017-03-312017-05-30$3.92 million-$0.91-$1.2627.78%
2016-12-312017-02-15$20.38 million-$1.54-$1.9018.95%
2016-09-302016-11-15$N/A-$1.96-$1.80-8.89%
2016-06-302016-08-30$N/A-$1.47-$1.533.92%
2016-03-312016-05-16$N/A-$1.26-$1.5116.56%
2015-12-312016-02-17-$1.40-$1.6816.67%
2015-09-302015-11-12-$0.20-$0.3135.48%
2015-06-302015-08-13-$0.24-$0.2917.24%
2015-03-312015-05-06-$0.26-$0.2910.34%
2014-12-312015-02-12-$0.50-$0.6016.67%
2014-09-302014-11-17-$0.77-$0.56-37.5%
2014-06-302014-08-11-$0.57-$0.53-7.55%
2014-03-312014-05-15-$3.71-$2.85-30.18%
2013-12-312014-02-13-$3.15-$2.20-43.18%
2013-09-302013-11-07-$1.96-$0.63-211.11%
2013-06-302013-08-06-$0.42-$0.420%

Arcturus Therapeutics Holdings Inc (ARCT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Arcturus Therapeutics Holdings Inc (ARCT) Chart:

Arcturus Therapeutics Holdings Inc (ARCT) News:

Below you will find a list of latest news for Arcturus Therapeutics Holdings Inc (ARCT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Arcturus Therapeutics Holdings Inc (ARCT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-2050CALL0 0506.12TRUE00
2025-06-207.50CALL0 12219.31TRUE00
2025-06-20100CALL0 4286.34TRUE00
2025-06-2012.50.98CALL13 28081.5TRUE-0.2-0.17
2025-06-20150.33CALL0 26887.7FALSE00
2025-06-2017.50.09CALL0 561113.78FALSE00
2025-06-20200CALL0 1906143.62FALSE00
2025-06-2022.50CALL0 63128.47FALSE00
2025-06-20250.03CALL0 401132.39FALSE00
2025-06-20300.01CALL0 53187.89FALSE00
2025-06-20350CALL0 6411.29FALSE00
2025-06-2050PUT0 0465.51FALSE00
2025-06-207.50PUT0 55237.1FALSE00
2025-06-20100PUT0 42130.68FALSE00
2025-06-2012.51.18PUT0 173103.27FALSE00
2025-06-20152.59PUT11 16368.25TRUE2.590
2025-06-2017.50PUT0 273170.53TRUE00
2025-06-20200PUT0 0162.04TRUE00
2025-06-2022.50PUT0 1257.59TRUE00
2025-06-20250PUT0 1219.54TRUE00
2025-06-20300PUT0 0387.88TRUE00
2025-06-20350PUT0 0346.47TRUE00
2025-07-182.50CALL0 0570.32TRUE00
2025-07-1850CALL0 0325.35TRUE00
2025-07-187.50CALL0 074.56TRUE00
2025-07-18100CALL0 0140.46TRUE00
2025-07-1812.51.85CALL0 4556.8TRUE00
2025-07-18150.8CALL0 22104.17FALSE00
2025-07-1817.50CALL0 14096.21FALSE00
2025-07-18200CALL0 0119.94FALSE00
2025-07-1822.50CALL0 0165.97FALSE00
2025-07-18250CALL0 0173.18FALSE00
2025-07-182.50PUT0 0519.02FALSE00
2025-07-1850PUT0 0301.32FALSE00
2025-07-187.50PUT0 0141.88FALSE00
2025-07-18100.88PUT0 193.14FALSE00
2025-07-1812.51.51PUT0 451.01FALSE00
2025-07-18153.05PUT0 266.33TRUE00
2025-07-1817.50PUT0 0115.81TRUE00
2025-07-18200PUT0 0149.61TRUE00
2025-07-1822.50PUT0 0155.32TRUE00
2025-07-18250PUT0 0115.45TRUE00
2025-09-192.50CALL0 5240.15TRUE00
2025-09-1950CALL0 1131.22TRUE00
2025-09-197.50CALL0 2114.71TRUE00
2025-09-19100CALL0 7385.56TRUE00
2025-09-1912.52.5CALL0 3596.24TRUE00
2025-09-19151.46CALL0 4573.93FALSE00
2025-09-1917.50.9CALL0 19482.13FALSE00
2025-09-19200.5CALL0 24798.86FALSE00
2025-09-1922.50CALL0 2103.76FALSE00
2025-09-19250.2CALL0 24102.81FALSE00
2025-09-19300CALL0 2114.91FALSE00
2025-09-19350.45CALL1 225126.33FALSE0.450
2025-09-192.50PUT0 0884.23FALSE00
2025-09-1950PUT0 5187.19FALSE00
2025-09-197.50PUT0 16113.02FALSE00
2025-09-19100PUT0 13572.5FALSE00
2025-09-1912.52.05PUT0 6188.87FALSE00
2025-09-19153.6PUT0 14577.54TRUE00
2025-09-1917.50PUT0 5177.24TRUE00
2025-09-19200PUT0 072.64TRUE00
2025-09-1922.50PUT0 0104.28TRUE00
2025-09-19250PUT0 0110.49TRUE00
2025-09-19300PUT0 0196.06TRUE00
2025-09-19350PUT0 0188.85TRUE00
2025-12-192.50CALL0 0174.89TRUE00
2025-12-1950CALL0 0144.06TRUE00
2025-12-197.56CALL1 892.49TRUE60
2025-12-19104.5CALL0 3381.39TRUE00
2025-12-1912.53.18CALL0 378.29TRUE00
2025-12-19152.05CALL0 23681.28FALSE00
2025-12-1917.51.45CALL1 1275.02FALSE1.450
2025-12-19201.3CALL0 3479.25FALSE00
2025-12-1922.50.65CALL0 479.47FALSE00
2025-12-192.50PUT0 0245.59FALSE00
2025-12-1950PUT0 0128.61FALSE00
2025-12-197.50PUT0 580.88FALSE00
2025-12-19101.63PUT0 7470.23FALSE00
2025-12-1912.52.74PUT0 3786.09FALSE00
2025-12-19150PUT0 073.42TRUE00
2025-12-1917.50PUT0 078.07TRUE00
2025-12-19200PUT0 069.47TRUE00
2025-12-1922.50PUT0 081.54TRUE00

Latest ARCT Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST7$13.15
Jun 13, 2022 7:59 PM EST100$13.18
Jun 13, 2022 7:59 PM EST200$13.19
Jun 13, 2022 7:59 PM EST200$13.2
Jun 13, 2022 7:59 PM EST100$13.2

Arcturus Therapeutics Holdings Inc (ARCT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000746/0001193805-20-000746-index.htm
2019-06-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1768224/000000000019010412/0000000000-19-010412-index.htm
2020-05-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1768224/000000000020004351/0000000000-20-004351-index.htm
2019-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319018228/0000899243-19-018228-index.htm
2019-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319022258/0000899243-19-022258-index.htm
2019-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319022418/0000899243-19-022418-index.htm
2019-08-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319022619/0000899243-19-022619-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319023531/0000899243-19-023531-index.htm
2019-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319023769/0000899243-19-023769-index.htm
2019-09-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319024193/0000899243-19-024193-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026109/0000899243-19-026109-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026116/0000899243-19-026116-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026123/0000899243-19-026123-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026159/0000899243-19-026159-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319026165/0000899243-19-026165-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319028631/0000899243-19-028631-index.htm
2019-12-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924319028803/0000899243-19-028803-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005379/0000899243-20-005379-index.htm
2020-02-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005382/0000899243-20-005382-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005383/0000899243-20-005383-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005386/0000899243-20-005386-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005387/0000899243-20-005387-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320005389/0000899243-20-005389-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320016049/0000899243-20-016049-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320016050/0000899243-20-016050-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320016410/0000899243-20-016410-index.htm
2020-09-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320024363/0000899243-20-024363-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320026884/0000899243-20-026884-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000089924320030320/0000899243-20-030320-index.htm
2020-04-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1768224/000092963820000538/0000929638-20-000538-index.htm
2020-09-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1768224/000110465920104394/0001104659-20-104394-index.htm
2020-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1768224/000110465920113789/0001104659-20-113789-index.htm
2019-03-18S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1768224/000119312519077140/0001193125-19-077140-index.htm
2019-04-11S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1768224/000119312519104005/0001193125-19-104005-index.htm
2019-04-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1768224/000119312519104054/0001193125-19-104054-index.htm
2019-04-12424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1768224/000119312519105243/0001193125-19-105243-index.htm
2019-06-148-K12BNotification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b)https://www.sec.gov/Archives/edgar/data/1768224/000119312519173808/0001193125-19-173808-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519176112/0001193125-19-176112-index.htm
2019-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519176908/0001193125-19-176908-index.htm
2019-06-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1768224/000119312519178934/0001193125-19-178934-index.htm
2019-07-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1768224/000119312519202684/0001193125-19-202684-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519205403/0001193125-19-205403-index.htm
2019-08-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119312519212073/0001193125-19-212073-index.htm
2019-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519212082/0001193125-19-212082-index.htm
2019-08-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119312519212590/0001193125-19-212590-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519212594/0001193125-19-212594-index.htm
2019-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519221871/0001193125-19-221871-index.htm
2019-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519245891/0001193125-19-245891-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519252227/0001193125-19-252227-index.htm
2019-09-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119312519257362/0001193125-19-257362-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519257389/0001193125-19-257389-index.htm
2019-10-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1768224/000119312519259220/0001193125-19-259220-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519280541/0001193125-19-280541-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519287260/0001193125-19-287260-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312519287407/0001193125-19-287407-index.htm
2019-12-12S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000119312519312823/0001193125-19-312823-index.htm
2020-05-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1768224/000119312520150308/0001193125-20-150308-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119312520164097/0001193125-20-164097-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380519000694/0001193805-19-000694-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000030/0001193805-20-000030-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000295/0001193805-20-000295-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000335/0001193805-20-000335-index.htm
2020-03-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000411/0001193805-20-000411-index.htm
2020-03-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000412/0001193805-20-000412-index.htm
2020-04-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000486/0001193805-20-000486-index.htm
2020-04-16S-3MEFRegistration adding securities to prior Form S-3 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000491/0001193805-20-000491-index.htm
2020-04-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000494/0001193805-20-000494-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000535/0001193805-20-000535-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000565/0001193805-20-000565-index.htm
2020-05-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000119380520000569/0001193805-20-000569-index.htm
2020-05-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000600/0001193805-20-000600-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000622/0001193805-20-000622-index.htm
2020-05-22S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000119380520000627/0001193805-20-000627-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000704/0001193805-20-000704-index.htm
2020-06-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000721/0001193805-20-000721-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000742/0001193805-20-000742-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000743/0001193805-20-000743-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000744/0001193805-20-000744-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000745/0001193805-20-000745-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000746/0001193805-20-000746-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000886/0001193805-20-000886-index.htm
2020-07-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000900/0001193805-20-000900-index.htm
2020-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000902/0001193805-20-000902-index.htm
2020-07-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1768224/000119380520000907/0001193805-20-000907-index.htm
2020-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000939/0001193805-20-000939-index.htm
2020-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000940/0001193805-20-000940-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520000987/0001193805-20-000987-index.htm
2020-08-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001021/0001193805-20-001021-index.htm
2020-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001022/0001193805-20-001022-index.htm
2020-08-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001052/0001193805-20-001052-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001229/0001193805-20-001229-index.htm
2020-10-02PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001230/0001193805-20-001230-index.htm
2020-10-13DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001272/0001193805-20-001272-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000119380520001274/0001193805-20-001274-index.htm
2019-06-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000120919119039011/0001209191-19-039011-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1768224/000120919120031641/0001209191-20-031641-index.htm
2019-06-21S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000156459019023153/0001564590-19-023153-index.htm
2019-06-26SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1768224/000156459019023496/0001564590-19-023496-index.htm
2019-06-26S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1768224/000156459019023504/0001564590-19-023504-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1768224/000156459019032166/0001564590-19-032166-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1768224/000156459019042017/0001564590-19-042017-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1768224/000156459020011037/0001564590-20-011037-index.htm
2020-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000156459020017147/0001564590-20-017147-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1768224/000156459020017549/0001564590-20-017549-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1768224/000156459020023633/0001564590-20-023633-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1768224/000156459020038980/0001564590-20-038980-index.htm
2019-04-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1768224/999999999519000693/9999999995-19-000693-index.htm
2019-07-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1768224/999999999519001724/9999999995-19-001724-index.htm
2020-05-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1768224/999999999520001236/9999999995-20-001236-index.htm
2020-06-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1768224/999999999520001665/9999999995-20-001665-index.htm
2019-07-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1768224/999999999719006174/9999999997-19-006174-index.htm
2020-02-03SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1768224/999999999720000424/9999999997-20-000424-index.htm
2020-02-24SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1768224/999999999720000993/9999999997-20-000993-index.htm

Arcturus Therapeutics Holdings Inc (ARCT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arcturus Therapeutics Holdings Inc (ARCT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1843%
Institutional Ownership: 7046%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-08-29Joseph E PaynePresident and CEOBuy5,000.0011.2256,100.001,474,097.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319022619/0000899243-19-022619-index.htm
2020-06-10Joseph E PaynePresident and CEOBuy1,000.0031.6931,690.001,475,097.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320016050/0000899243-20-016050-index.htm
2019-09-13Magda MarquetDirectorBuy2,300.0010.5824,334.0022,720.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319023769/0000899243-19-023769-index.htm
2019-08-23ANDY SASSINEChief Financial OfficerBuy10,000.0010.90109,000.00247,596.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319022418/0000899243-19-022418-index.htm
2019-12-03ANDY SASSINEChief Financial OfficerBuy10,000.0010.00100,000.00257,596.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319028631/0000899243-19-028631-index.htm
2019-12-05ANDY SASSINEChief Financial OfficerBuy5,649.009.7354,964.77268,245.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319028803/0000899243-19-028803-index.htm
2020-06-10ANDY SASSINEChief Financial OfficerBuy5,000.0029.74148,700.00273,245.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320016049/0000899243-20-016049-index.htm
2020-05-20Ultragenyx Pharmaceutical Inc.DirectorBuy600,000.0016.009,600,000.003,000,000.00https://www.sec.gov/Archives/edgar/data/1768224/000120919120031641/0001209191-20-031641-index.htm
2019-08-19PETER C FARRELLDirectorBuy4,681.0011.0251,584.6238,523.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319022258/0000899243-19-022258-index.htm
2019-08-20PETER C FARRELLDirectorBuy4,432.0010.8548,087.2042,955.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319022258/0000899243-19-022258-index.htm
2019-09-12Keith C KummerfeldOfficerBuy500.0010.695,346.70500.00https://www.sec.gov/Archives/edgar/data/1768224/000089924319023531/0000899243-19-023531-index.htm
2020-11-02Pad ChivukulaChief Scientific Officer & COOSell10,000.0055.28552,800.00702,548.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320030320/0000899243-20-030320-index.htm
2020-10-01Pad ChivukulaChief Scientific Officer & COOSell10,000.0042.83428,300.00712,548.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320026884/0000899243-20-026884-index.htm
2020-09-03Pad ChivukulaChief Scientific Officer & COOSell10,000.0045.16451,600.00722,548.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320024363/0000899243-20-024363-index.htm
2020-06-12Keith C KummerfeldOfficerBuy450.0033.3314,998.50950.00https://www.sec.gov/Archives/edgar/data/1768224/000089924320016410/0000899243-20-016410-index.htm